Eli Lilly stock jumps on weight-loss drug sales forecast

Shares of Eli Lilly (LLY) are moving higher on Tuesday morning as the company reported its first-quarter earnings results, revealing a 26% year-over-year revenue increase in a figure of $8.77 billion. Ultimately, this revenue print fell short of estimates ($8.92 billion). The pharmaceutical giant did, however, raise its annual sales forecast by $2 billion due to an insatiable demand for its GLP-1 weight-loss drugs Mounjaro and Zepbound.

Yahoo Finance Health Reporter Anjalee Khemlani joins Catalysts to break down the report and what it means for the company moving forward.

For more expert insight and the latest market action, click here to watch this full episode of Catalysts.

This post was written by Nicholas Jacobino